{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T22:24:52Z","timestamp":1781735092676,"version":"3.54.5"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,29]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>We report the first case to quantitatively demonstrate a rapid and substantial viral load reduction using long-acting cabotegravir and rilpivirine in the third trimester of pregnancy. This case underscores the challenges some pregnant individuals face with daily oral antiretroviral therapy and the potential role of long-acting injectables in select scenarios.<\/jats:p>","DOI":"10.1093\/ofid\/ofaf604","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T12:23:00Z","timestamp":1759234980000},"source":"Crossref","is-referenced-by-count":1,"title":["Third-Trimester HIV Viremia Treated With Long-Acting Cabotegravir and Rilpivirine: A Case Report"],"prefix":"10.1093","volume":"12","author":[{"given":"Noora","family":"Kazanji","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, University of Illinois at Chicago , Chicago, Illinois ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blake","family":"Max","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, University of Illinois at Chicago , Chicago, Illinois ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4101-4777","authenticated-orcid":false,"given":"Rodrigo M","family":"Burgos","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, University of Illinois at Chicago , Chicago, Illinois ,","place":["USA"]},{"name":"Department of Pharmacy Practice, University of Illinois at Chicago , Chicago, Illinois ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer T","family":"Pham","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, University of Illinois at Chicago , Chicago, Illinois ,","place":["USA"]},{"name":"Department of Pediatrics, Division of Neonatology, University of Illinois at Chicago , Chicago, Illinois ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine E","family":"Ford","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, University of Illinois at Chicago , Chicago, Illinois ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,10,1]]},"reference":[{"key":"2025102314040733300_ofaf604-B1","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1056\/NEJMoa1215541","article-title":"Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection","volume":"369","author":"Walmsley","year":"2013","journal-title":"N Engl J Med"},{"key":"2025102314040733300_ofaf604-B2","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1310\/hct1405-192","article-title":"Pharmacokinetics, safety, and monotherapy antiviral activity of GSK1265744, an HIV integrase strand transfer inhibitor","volume":"14","author":"Spreen","year":"2013","journal-title":"HIV Clin Trials"},{"key":"2025102314040733300_ofaf604-B3","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/hiv.13370","article-title":"Compassionate use of long-acting cabotegravir plus rilpivirine for people living with HIV-1 in need of parenteral antiretroviral therapy","volume":"24","author":"D'Amico","year":"2023","journal-title":"HIV Med"},{"key":"2025102314040733300_ofaf604-B4","author":"Short"},{"key":"2025102314040733300_ofaf604-B5","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1093\/cid\/ciae242","article-title":"Long-acting injectable cabotegravir and rilpivirine in a pregnant woman with HIV","volume":"79","author":"van der Wekken-Pas","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2025102314040733300_ofaf604-B6","doi-asserted-by":"crossref","first-page":"e26401","DOI":"10.1002\/jia2.26401","article-title":"Evaluation of long-acting cabotegravir safety and pharmacokinetics in pregnant women in eastern and Southern Africa: a secondary analysis of HPTN 084","volume":"28","author":"Delany-Moretlwe","year":"2025","journal-title":"J Int AIDS Soc"},{"key":"2025102314040733300_ofaf604-B7","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1001\/jama.2024.2985","article-title":"Updated treatment recommendation on use of cabotegravir and rilpivirine for people with HIV from the IAS-USA guidelines panel","volume":"331","author":"Sax","year":"2024","journal-title":"JAMA"},{"key":"2025102314040733300_ofaf604-B8","author":"U.S. Department of Health and Human Services"},{"key":"2025102314040733300_ofaf604-B9","doi-asserted-by":"crossref","first-page":"969","DOI":"10.7326\/M23-0788","article-title":"Demonstration project of long-acting antiretroviral therapy in a diverse population of people with HIV","volume":"176","author":"Gandhi","year":"2023","journal-title":"Ann Intern Med"},{"key":"2025102314040733300_ofaf604-B10","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1093\/cid\/ciae500","article-title":"Viral suppression rates at 48 weeks in people with HIV starting long-acting cabotegravir\/rilpivirine with initial viremia","volume":"80","author":"Hickey","year":"2025","journal-title":"Clin Infect Dis"},{"key":"2025102314040733300_ofaf604-B11","author":"Elion"},{"key":"2025102314040733300_ofaf604-B12","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1056\/NEJMoa1904398","article-title":"Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression","volume":"382","author":"Swindells","year":"2020","journal-title":"N Engl J Med"},{"key":"2025102314040733300_ofaf604-B13","doi-asserted-by":"crossref","first-page":"e185","DOI":"10.1016\/S2352-3018(20)30340-4","article-title":"Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study","volume":"8","author":"Orkin","year":"2021","journal-title":"Lancet HIV"},{"key":"2025102314040733300_ofaf604-B14","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1093\/cid\/ciad020","article-title":"Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with human immunodeficiency virus 1 type 1 infection: 152-week results from ATLAS-2M, a randomized, open-label, phase 3b, noninferiority study","volume":"76","author":"Overton","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2025102314040733300_ofaf604-B15","author":"Shankaran"},{"key":"2025102314040733300_ofaf604-B16","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1093\/cid\/ciad370","article-title":"Expanded multivariable models to assist patient selection for long-acting cabotegravir + rilpivirine treatment: clinical utility of a combination of patient, drug concentration, and viral factors associated with virologic failure","volume":"77","author":"Orkin","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2025102314040733300_ofaf604-B17","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1086\/505356","article-title":"Rationale and uses of a public HIV drug-resistance database","volume":"194","author":"Shafer","year":"2006","journal-title":"J Infect Dis"},{"key":"2025102314040733300_ofaf604-B18","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1177\/0956462418797847","article-title":"Crushed dolutegravir\/abacavir\/lamivudine given via nasogastric tube in gastric outlet obstruction caused by cancer resulted in rapid viral load suppression","volume":"30","author":"Chrdle","year":"2018","journal-title":"Int J STD AIDS"},{"key":"2025102314040733300_ofaf604-B19","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1001\/jama.285.6.709","article-title":"Understanding the timing of HIV transmission from mother to infant","volume":"285","author":"Kourtis","year":"2001","journal-title":"JAMA"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofaf604\/64458090\/ofaf604.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/12\/10\/ofaf604\/64458090\/ofaf604.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/12\/10\/ofaf604\/64458090\/ofaf604.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T18:04:14Z","timestamp":1761242654000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofaf604\/8269506"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,29]]},"references-count":19,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,9,29]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofaf604","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10]]},"published":{"date-parts":[[2025,9,29]]},"article-number":"ofaf604"}}